CDMOs and CROs at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
62 CDMOs and CROs are at Festival of Biologics 2026 — 26 presentations on the program and 55 with a booth in the exhibit hall. Most represented: Lonza (6 on the program), Pharmaron (2 on the program), Provis Biolabs (2 on the program). 57 of them have their own page in this guide. As of Sep 26, 2026.
Topic
Top represented
Showing 1–13 of 62 organizations
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Lonza Basel, Switzerland | |
Contract development and manufacturing partner for biologics, cell and gene therapies and small molecules. | Booth Exhibiting at Booth 450 Talk Tue Oct 13 17:10 De-risking Lyophilization Scale-Up Using predictive models How computer models of freeze-drying can predict what happens at full manufacturing scale, cutting experiments and the risk of a failed transfer. Keynote Wed Oct 14 09:55 From Experimentation to Prediction: How Data-Driven Innovation is Forging Predictability Across Biologics Development and Precision Biomanufacturing Why biologics developers still decide by trial and error, and how treating every program as shared learning could make outcomes more predictable. Bioprocessing & manufacturingAI & computational design Talk Wed Oct 14 12:30 Accelerating CHO Cell Line Development Through Next-Generation Expression System Design How improved cell engineering, promoter design and selection methods shorten the path from DNA to a cell line that makes a drug. Talk Wed Oct 14 14:30 Beyond mAbs: accelerated Gene-to-IND development for bispecifics, Fc-fusions and high-concentration biologics Faster routes from DNA to first clinical trials for complex antibody drugs, and the problems they create in making, purifying and formulating them. |
Pharmaron Beijing, China | |
R&D service company supporting biologics from discovery to commercialization with integrated laboratory, preclinical, development, manufacturing and regulatory services. | Booth Exhibiting at Booth 406 Talk Wed Oct 14 17:10 Successful CMC Development & Manufacturing is Built on Highly Effective Partnerships Why complex biologic drugs rely on close partnerships in manufacturing and quality control to move from preclinical work to clinical supply. Chair Thu Oct 15 08:55 Chair Thu Oct 15 11:15 |
Indian company developing biosimilars and offering biologics CDMO services plus research- and GMP-grade recombinant reagents. | Chair Wed Oct 14 14:05 Keynote Thu Oct 15 09:30 From Molecule to Market: De-Risking Biosimilar Development and Commercialization How to lower the risks of bringing biosimilars, close copies of approved biologic drugs, to market as approval paths grow simpler. |
Selvita Kraków, Poland | |
Preclinical contract research organization supporting drug discovery and development studies. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 17:10 Developability of antibodies: challenges and future directions Why many antibody drug candidates still fail late over poor stability or clumping, and how automated screening and AI could catch problems earlier. |
Clinical research organization running clinical trials and offering regulatory and market-access consulting for drug developers. | Panel Tue Oct 13 17:30 Talk Tue Oct 13 17:50 |
Develops a scalable platform for crystallizing biologic drugs in microgravity, targeting high-concentration, low-viscosity formulations. | Booth Exhibiting (no floor booth listed) |
Booth Exhibiting (no floor booth listed) Talk Tue Oct 13 15:10 Image-Based Monoclonality Assurance for Biotherapeutic Cell Lines: Evaluating Clone Outgrowth and Suspension Adaptation Following Single-Cell Isolation How images of single seeded cells help show regulators a production cell line grew from one cell, compared across three cell types. | |
Contract development and manufacturing organization for biologics, vaccines and advanced therapies. | Booth Exhibiting at Booth 408 Keynote Tue Oct 13 12:40 |
Family-owned CRDMO combining preclinical research and clinical manufacturing of therapeutic proteins from mammalian cells at one site. | Booth Exhibiting at Booth 224 Talk Wed Oct 14 14:50 Designing Manufacturability into Multispecifics Early: How Integrated CRDMO De-risks Biologics Programs and Accelerates Development Why checking how easy complex biologics are to make before picking a final candidate leads to faster, cheaper, lower-risk development. |
KBI Biopharma Durham, NC | |
Contract development and manufacturing organization for biologics, from cell line development to clinical and commercial production. | Booth Exhibiting at Booth 294 Talk Tue Oct 13 17:10 Smarter lead selection and faster representative material for early CMC studies How inserting genes with a transposase and growing stable cell pools helps teams pick lead molecules and make realistic early batches sooner. |
Puerto Rico-based biologics CDMO offering development, manufacturing and flexible fill-finish capacity for sponsors seeking US-made biologics. | Booth Exhibiting (no floor booth listed) Panel Wed Oct 14 17:30 PANEL DISCUSSION: From Contract to Collaboration: Effective CDMO Strategies for Biopharma Manufacturing How drug makers and contract manufacturers can work as true partners, sharing process know-how and handling changes as production scales up. |
ProBioGen Berlin, Germany | |
Offers cell line development, process development and GMP manufacturing of biologics, plus glyco-engineering and viral vaccine production technologies. | Booth Exhibiting at Booth 180 Talk Tue Oct 13 14:30 Navigating Speed, Complexity, and Scalability in Biomanufacturing Selecting Phase-Appropriate Upstream Strategies from Rapid Platform to Intensified Processes How a contract manufacturer matches cell culture methods to each development stage, weighing quick standard batches against more efficient continuously fed ones. |
Thermo Fisher Scientific Waltham, MA | |
Life sciences supplier whose CDMO and clinical services business offers integrated development, manufacturing and clinical supply for pharma and biotech. | Booth Exhibiting at Booth 357 Talk Tue Oct 13 17:30 The science behind robust cell line development to produce complex biologic therapies How transposase gene insertion, AI-driven analysis and more intensive cell culture shorten the path from new cell line to first clinical trials. |
Instantly find 20 buyers from CDMOs and CROs
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Festival of Biologics 2026 by
Organization type
Topic
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Exhibit hall
Everyone
Not affiliated with or endorsed by Terrapinn or the Festival of Biologics. Submit a correction